Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LL-37 oral antiviral polypeptide vs Lactococcus lactis in COVID-19
ChiCTR2200063622Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ll-37 in coronavirus pneumonia (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Upper respiratory tract nucleic acid test, Lung CT imaging and 1 more. Started Sep 2022; status: recruiting.
02
Drugs
ll-37
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on ChiCTR2200063622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063622.